Lazurenko K. A., Trophymenko I. O., Gavryliuk V. G., Kurahina N. V., Lavrentieva K. V., Sklyar T. V.

RESEARCH OF THE COMPOSITION OF THE INTESTINAL MICROBIOME IN DYSBIOTIC DISORDERS IN PATIENTS OF DIFFERENT AGE GROUPS

---

Show/Download

About the author:

Lazurenko K. A., Trophymenko I. O., Gavryliuk V. G., Kurahina N. V., Lavrentieva K. V., Sklyar T. V.

Heading:

MICROBIOLOGY

Type of article:

Scientific article

Annotation:

This study conducted a microbiological investigation of dysbiotic disorders of the intestinal microbiome in patients of different ages with diseases of specific biotopes of the digestive system. As a result of the examination of 145 patients of different age categories, dysbiotic changes in the composition of the intestinal microbiota were detected in terms of quantitative and qualitative indicators: a decrease in the titres of symbiotic microbiota – bacteria of the genera Lactobacillus, Bifidobacterium, Enterococcus, typical Escherichia against the background of an increase in the concentration of representatives of conditionally pathogenic microbiota: lactose-negative and haemolytic atypical strains of E. coli. Enterococcus, typical Escherichia against the back ground of an increase in the concentration of representatives of conditionally pathogenic microbiota: lactose-negative and haemolytic atypical strains of E. coli, Clostridium spp., Staphylococcus spp., Proteus spp. and yeast-like fungi Candida spp. The most significant deviations in the composition of the intestinal microbiota were recorded in individuals in the second age group. The highest frequency of dysbiotic disorders was found in patients with various intestinal pathologies – 47.6% and stomach pathologies – 35.9% of cases. The lowest number of cases of dysbiosis was recorded in patients with liver diseases – 9.0% and pancreas diseases – 13.1%. It was shown that all isolated strains were susceptible to most antibiotics. The most active antibiotic against all studied strains of S. aureus was imipenem, to which all strains were sensitive, as well as gatifloxacin and rifampicin, which inhibited the growth of 92.1% and 78.9% of Staphylococcus aureus strains, respectively. The isolated E. coli isolates were characterised by sensitivity to ciprofloxacin, cefuroxime, cefotaxime, cefoperazone, cefepime, polymyx in and levofloxacin. Proteus spp. strains showed the highest sensitivity to ciprofloxacin, amikacin, cefotaxime and cefepime and resistance to doxycycline. The isolated Enterococcus spp. strains were sensitive to linezolid and ampicillin, and resistant to norfloxacin, ciprofloxacin, co-trimoxazole, and aztreonam. All C. difficile strains were sensitive to metronidazole, vancomycin, and amoxicillin/clavulanate. More than 90% of them were resistant to penicillin, and 58.1% of isolates were resistant to imipenem.

Tags:

Bibliography:

1. Dabke K, Hendrick G, Devkota S. The gut microbiome and metabolic syndrome. J Clin Invest. 2019;129(10):4050-4057. DOI: 10.1172/JCI129194.
2. Radjabzadeh D, Boer CG, Beth SA, Van der Wal P, Kiefte-De Jong JC, Jansen MAE, et al. Diversity, compositional and functional differences between gut microbiota of children and adults. Sci Rep. 2020;10:1077-1085. DOI: 10.1038/s41598-020-57734-z.
3.  Vargas A, Robinson BL, Houston K, Vilela Sangay AR, Saadeh M, D’Souza S, et al. Gut microbiota-derivedmetabolites and chronic inflammatory diseases. Explor Med. 2025;6:1001275. Available from: .
4.  Gilbert JA, Blaser MJ, Caporaso JG, Jansson JK, Lynch SV, Knight R. Current understanding of the human microbiome. Nat Med. 2018;24(4):392-400. DOI: 10.1038/nm.4517.
5.  Ronan V, Yeasin R, Claud EC. Childhood Development and the Microbiome-The Intestinal Microbiota in Maintenance of Health and Development of Disease During Childhood Development. Gastroenterology. 2021;160(2):495-506. DOI: 10.1053/j.gastro.2020.08.065.
6.  Saeed NK, Al-Beltagi M, Bediwy AS, El-Sawaf Y, Toema O. Gut microbiota in various childhood disorders: Implication and indications. World J Gastroenterol. 2022;28(18):1875-1901. DOI: 10.3748/wjg.v28.i18.1875.
7.  Ivanova A, Ialovenko O, Duhan O. Microboim kyshechnika liudyny: naukovo-praktychni zasady ta dosiagnennia. Proceedings of the 5th International Scientific and Practical Conference Theory and practice of science: key aspects; 2021 Nov 7-8; Rome. Rome: Dana; 2021. p. 231-260. [in Ukrainian].
8.  Kastl AJ Jr, Terry NA, Wu GD, Albenberg LG. The Structure and Function of the Human Small Intestinal Microbiota: Current Understanding and Future Directions. Cell Mol Gastroenterol Hepatol. 2020;9(1):33-45. DOI: 10.1016/j.jcmgh.2019.07.006.
9. Yankovsky DS, Shirobokov VP, Dyment GS. The role of microbiome in the formation of child health. Modern Pediatrics. 2019;5(101):64-111. DOI: 10.15574/SP.2019.101.64.
10.  Hurina SV. Mikroekolohiia kyshenyka u ditei rannoho viku na foni hostroho obstruktyvnoho bronkhitu. Sumy: SumDU; 2017. 66 s. [in Ukrainian].
11.  Reid G, Jass J, Sebulsky MT, McCormick JK. Potential uses of probiotics in clinical practice. Clin Microbiol Rev. 2003;16(4):658-72. DOI:10.1128/CMR.16.4.658-672.2003.
12.  Shayista H, Nagendra Prasad MN, Niranjan Raj S, Prasad A, Lakshmi S, Ranjini HK, et al. Complexity of antibiotic resistance and its impact on gut microbiota dynamics. Engineering Microbiology. 2025;5(1):100187. DOI: https://doi.org/10.1016/j.engmic.2024.100187.
13.  Xu L, Surathu A, Raplee I, Chockalingam A, Stewart S, Walker L, et al. The effect of antibiotics on the gut microbiome: a metagenomics analysis of microbial shift and gut antibiotic resistance in antibiotic treated mice. BMC Genomics. 2020;21(1):263. DOI: 10.1186/s12864-020-6665-2.
14.  Francino MP. Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances. Front Microbiol. 2016;6:1543. DOI:10.3389/fmicb.2015.01543.
15.  Pérez-Cobas AE, Gosalbes MJ, Friedrichs A, Knecht H, Artacho A, Eismann K, et al. Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut. 2013;62(11):1591-601. DOI: 10.1136/gutjnl-2012-303184.
16.  Zhang Q, Cheng L, Wang J, Hao M, Che H. Antibiotic-Induced Gut Microbiota Dysbiosis Damages the Intestinal Barrier, Increasing Food Allergy in Adult Mice. Nutrients. 2021;13(10):3315. DOI: 10.3390/nu13103315.
17.  Dahiya D, Nigam PS. Antibiotic-Therapy-Induced Gut Dysbiosis Affecting Gut Microbiota-Brain Axis and Cognition: Restoration by Intake of Probiotics and Synbiotics. Int J Mol Sci. 2023;24(4):3074. DOI: 10.3390/ijms24043074.
18.  Brenner DJ, Krieg NR, Staley JT, Garrity GM, editors. Bergey’s Manual of Systematic Bacteriology. 2nd ed. Vol. 2, Part B. New York: Springer; 2005. Chapter, Enterobacteriaceae; p. 587–607.
19.  Instytut hastroenterolohii NAMNU. Instruktsiia doslidzhennia stanu mikroflory kyshenyka za dopomohoiu mikrobiolohichnykh metodiv. Dnipro: Instytut hastroenterolohii NAMNU; 2023. 10 s. [in Ukrainian].
20.  CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 11th ed. CLSI standart M07. Wayne, PA: Clinical and Laboratory Standarts Institute; 2018. 13 p. Аvailable from: https://clsi.org/ media/1928/m07ed11_sample.pdf.
21. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2020. 332 p. Аvailable from: https://www.nih.org.pk/wpcontent/ uploads/2021/02/CLSI-2020.pdf.
22.  Mohapatra D, Debata N, Singh S. Extensively drug-resistant and pandrug-resistant Gram-negative bacteria in a tertiary-care hospital in Eastern India: A 4-year retrospective study. Journal of Global Antimicrobial Resistance. 2018;15:246-249. DOI: 10.1016/j.jgar.2018.08.010.
23.  Zhao Q, Chen Y, Huang W, Zhou H, Zhang W. Drug-microbiota interactions: an emerging priority for precision medicine. Signal Transduct Target Ther. 2023;8(1):386. DOI: 10.1038/s41392-023-01619-w.
24.  Gilmore MS, Clewell DB, Ike Y, Shankar N, editors. Enterococci: From Commensals to Leading Causes of Drug Resistant Infection. Boston: Massachusetts Eye and Ear Infirmary; 2014. Chapter, Enterococcal Infection - Treatment and Antibiotic Resistance. Available from: .
25.  Mohr JF, Friedrich LV, Yankelev S, Lamp KC. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). International Journal of Antimicrobial Agents. 2009;33(6):543-548 DOI: 10.1016/j.ijantimicag.2008.12.007.
26.  Garey KW, Dao-Tran TK, Jiang ZD, Price MP, Gentry LO, Dupont HL. A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics. J Hosp Infect. 2008;70(2):142-7. DOI: 10.1016/j.jhin.2008.06.026.
27.  Huang H, Weintraub A, Fang H, Nord CE. Antimicrobial resistance in Clostridium difficile. Int J Antimicrob Agents. 2009;34(6):516-22. DOI:10.1016/j.ijantimicag.2009.09.012.

Publication of the article:

«Bulletin of problems biology and medicine», Issue 2,177, 383-401 pages, index UDC 616.34-002.1:579.61

DOI:

10.29254/2077-4214-2025-2-177-383-401